Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS

Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)

NCT02231918 ·Status: COMPLETED ·Phase: PHASE2

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

NCT00152958 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

NCT00275457 ·Status: COMPLETED ·Phase: PHASE3

Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS

NCT05214963 ·Status: COMPLETED ·Phase: NA

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome

NCT02025608 ·Status: COMPLETED ·Phase: PHASE4

Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)

NCT01382901 ·Status: COMPLETED ·Phase: PHASE2

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

NCT00152997 ·Status: COMPLETED ·Phase: PHASE2

Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

NCT01084551 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663 ·Status: COMPLETED ·Phase: PHASE2

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

NCT00539461 ·Status: COMPLETED

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

NCT01214109 ·Status: COMPLETED ·Phase: PHASE1

Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome

NCT01823770 ·Status: COMPLETED ·Phase: PHASE4

Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)

NCT04874155 ·Status: COMPLETED ·Phase: NA

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

NCT00627003 ·Status: COMPLETED ·Phase: PHASE3

Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)

NCT00887289 ·Status: COMPLETED

XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.

NCT00298623 ·Status: COMPLETED ·Phase: PHASE3

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome

NCT01455012 ·Status: COMPLETED ·Phase: PHASE4

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854 ·Status: COMPLETED ·Phase: PHASE3

Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers

NCT02264132 ·Status: COMPLETED ·Phase: PHASE1

Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

NCT00136045 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

NCT00355641 ·Status: COMPLETED ·Phase: PHASE3

Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery

NCT06745492 ·Status: COMPLETED

Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome

NCT00530790 ·Status: COMPLETED ·Phase: PHASE2

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

NCT00666965 ·Status: COMPLETED ·Phase: PHASE2